



IFW

PATENT
ATTORNEY DOCKET NO. 00786/425002

Certificate of Mailing: Date of Deposit: 11/08/05

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Antonio J. Freitas

Printed name of person mailing correspondence

Antonio J. Freitas
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Clifford J. Woolf	Art Unit:	Not yet assigned
Serial No.:	10/510,266	Examiner:	Not yet assigned
Filed:	October 5, 2004	Customer No.:	21559
Title:	COMPOSITIONS AND METHODS FOR PREVENTING ABUSE OF ORALLY ADMINISTERED MEDICATIONS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 08 November 2005



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/425002
		Serial No.	10/510,266
		Applicant	Clifford J. Woolf
		Filing Date	October 5, 2004
		Group	Not yet assigned
		IDS Filed	November 8, 2005

U.S. PATENT DOCUMENTS						
Examiner=s Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,688,825	Nov. 18, 1997	Makriyannis et al.			
	6,277,398	Aug. 21, 2001	Caruso			
	US 2003/0004177	Jan. 2, 2003	Kao et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner=s Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 03/092676	Nov. 13, 2003	WIPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Blom et al., "The Long-Term Effects of Capsaicin Aqueous Spray on the Nasal Mucosa," <i>Clin. Exp. Allergy</i> 28:1351-1358 (1998).					
	Dasgupta et al., "Treating the Human Bladder with Capsaicin: Is it Safe?," <i>Eur. Urol.</i> 33:28-31 (1998).					
	Donnerer et al., "Absorption and Metabolism of Capsaicinoids Following Intragastric Administration in Rats," <i>Naunyn-Schmied. Arch. Pharmacol.</i> 342(3):357-361 (1990). [Abstract]					
	Gilchrist et al., "Enhanced Withdrawal Responses to Heat and Mechanical Stimuli Following Intraplantar Injection of Capsaicin in Rats," <i>Pain</i> 67(1):179-88 (1996).					
	Holzer, "Neural Injury, Repair, and Adaptation in the GI Tract II. The Elusive Action of Capsaicin on the Vagus Nerve," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> 275(1):G8-G13 (1998).					
	Laird et al., "Role of Central and Peripheral Tachykinin NK1 Receptors in Capsaicin-Induced Pain and Hyperalgesia in Mice," <i>Pain</i> 90(1-2):97-103 (2001).					
	Liu et al., "A Non-Pungent Resiniferatoxin Analogue, Phorbol 12-Phenylacetate 13 Acetate 20-Homovanillate, Reveals Vanilloid Receptor Subtypes on Rat Trigeminal Ganglion Neurons," <i>Neuroscience</i> 84(2):569-581 (1998).					
	Seno and Dray, "Capsaicin-Induced Activation of Fine Afferent Fibres From Rat Skin In Vitro," <i>Neuroscience</i> 55(2):563-569 (1993).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/425002
		Serial No.	10/510,266
		Applicant	Clifford J. Woolf
		Filing Date	October 5, 2004
		Group	Not yet assigned
		IDS Filed	November 8, 2005

	Sietsema et al., "The Antinociceptive Effect and Pharmacokinetics of Olvanil Following Oral and Subcutaneous Dosing in the Mouse," <i>Life Sci.</i> 43(17):1385-1391 (1988).
	Szallasi and Blumberg, "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacol. Rev.</i> 51(2):159-211 (1999).
	"Chemistry of Opioid Analgesics," Neurology Pharmacotherapeutics Lecture Notes, Wayne State University, (2002).
	Copy of International Search Report for PCT/US03/12496.
	"Mind Over Matter Teacher's Guide - Opiates," National Institute on Drug Abuse (2002).
	Nerac.com Search Report "Capsaicin and Repellent/Deterrent," February 18, 2002.
	Nerac.com Search Report "Capsaicin and Repellent /Deterrent," February 19, 2002.
	"Prescription Drugs: Abuse and Addiction," National Institute on Drug Abuse, NIH Publication Number 01-4881:1-12 (2001).
	Reference List pp.7-12.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	